Mutational impact of chemotherapy on the whole-genome of therapy-related tumor. (A) Proportional contribution of SBS, DBS, and ID mutational signatures in each tumor sample. Each column represents a unique patient. Samples are annotated by disease histology and therapy exposure. Asterisk denotes the only patient exposed to low-dose melphalan without transplantation. (B) Boxplots for the number of SBS for platinum/melphalan-exposed tMN compared with de novo AML and other tMN. (C) Boxplot for E-DBS3 and E-DBS9 in platinum-exposed and -unexposed tMN. (D) Boxplot for ID8 in de novo AML, tMN with chemotherapy mutational signatures, and tMN without chemotherapy mutational signatures. Dots with orange borders are from patients exposed to radiation.